Odyssey Therapeutics Inc. Common Stock (ODTX)
Stock · NASDAQ · Health Care
$17.21as of 10/16/2026
Price chart
Active signals
Support level
$16.43
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
About ODTX
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammato…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 100
- Website
- odysseytx.com
Fundamentals
- 1-day range
- $16.36$17.75
- Market cap
- $1.04B
- P/E (trailing)
- —
- P/E (forward)
- -4.23
- EPS (trailing)
- $-5.71
- Dividend yield
- —
- Beta
- -0.45
- Avg. volume
- 266.2K
52-week range
$15.1$29.05
Next earnings: November 5, 2026 · EPS estimate $-0.96
Forecasts
6 analyst ratings
Buy 92%
Hold 8%
Sell 0%
1-year price forecast
High
$44
+155.7%
Median
$35
+103.4%
Low
$27
+56.9%
Odyssey Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ODTXOdyssey Therapeutics Inc. Common Stock$17.17▼ 2.28%Market cap $1.04BP/E —$15.1$29.05
- REPLReplimune Group Inc. Common Stock$10.86▼ 7.57%Market cap $1.08BP/E —$1.5$16.33
- CGEMCullinan Therapeutics Inc. Common Stock$12.93▼ 7.64%Market cap $1.10BP/E —$6.73$23.19
- SANASana Biotechnology Inc. Common Stock$2.27▼ 8.28%Market cap $948.97MP/E —$2.32$6.55
- ATTOAttovia Therapeutics Inc. Common Stock$13.73▼ 7.10%Market cap $928.90MP/E 0.00$14.23$28
- MGTXMeiraGTx Holdings plc Ordinary Shares$9.28▼ 6.17%Market cap $1.18BP/E 11.93$6.62$15.35
- ALVOAlvotech Ordinary Shares$5▼ 5.84%Market cap $1.19BP/E —$2.94$9.05
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ODTX Odyssey Therapeutics Inc. Common Stock | $1.04B | — | $17.17 | ▼ 2.28% | $15.1$29.05 |
| REPL Replimune Group Inc. Common Stock | $1.08B | — | $10.86 | ▼ 7.57% | $1.5$16.33 |
| CGEM Cullinan Therapeutics Inc. Common Stock | $1.10B | — | $12.93 | ▼ 7.64% | $6.73$23.19 |
| SANA Sana Biotechnology Inc. Common Stock | $948.97M | — | $2.27 | ▼ 8.28% | $2.32$6.55 |
| ATTO Attovia Therapeutics Inc. Common Stock | $928.90M | 0.00 | $13.73 | ▼ 7.10% | $14.23$28 |
| MGTX MeiraGTx Holdings plc Ordinary Shares | $1.18B | 11.93 | $9.28 | ▼ 6.17% | $6.62$15.35 |
| ALVO Alvotech Ordinary Shares | $1.19B | — | $5 | ▼ 5.84% | $2.94$9.05 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Odyssey Therapeutics to Present OD-001 Data at UEG Week 2026
Odyssey Therapeutics announced that it will present additional Phase 2a induction data for its drug OD-001 in ulcerative colitis at the UEG Week 2026 conference. This upcoming presentation provides new clinical information on the company's lead candidate. The stock is currently trading near its 52-week low, with an average analyst target price of $35.75.
Odyssey Therapeutics to Present OD-001 Data at UEG Week 2026. Odyssey Therapeutics announced that it will present additional Phase 2a induction data for its drug OD-001 in ulcerative colitis at the UEG Week 2026 conference. This upcoming presentation provides new clinical information on the company's lead candidate. The stock is currently trading near its 52-week low, with an average analyst target price of $35.75.